NanoVibronix Inc (Nasdaq: NAOV), a medical device company headquartered in Elmsford, New York, on Tuesday announced the signing of a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (RCT) study of UroShield.
This clinical study aims to gather additional evidence supporting NanoVibronix's application to the FDA for permanent clearance of the UroShield device.
The company' proprietary technology, which utilises patented low-intensity surface acoustic wave (SAW) technology, allows for the creation of low-frequency ultrasound waves that can be used for medical applications such as disruption of biofilms and bacterial colonisation, as well as for pain relief.
NanoVibronix's primary products, PainShield and UroShield, are portable devices designed for home use without the need for medical professional assistance.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration